DAJY(002030)2023-06-14 12:16Group 1: Financial Performance - In 2022, the company's total revenue was approximately 12 billion CNY, with over 8 billion CNY from COVID-19 testing kits and around 3 billion CNY from other routine testing kits [1] - The sales volume of routine testing products in Q1 2023 remained stable compared to the same period in 2019, despite a significant increase in shipment volume [1] - The price of some testing kits has decreased by over 30% in the past two years, impacting revenue [1] Group 2: Strategic Decisions - The company issued a price adjustment notice to respond to national policies aimed at making healthcare more affordable and accessible [2] - The decision to lower prices is also based on the company's ability to control and reduce production costs through scaled manufacturing [2] - The company has been preparing to expand its product range into the IVD (In Vitro Diagnostics) field for several years, leveraging its established subsidiaries [2] Group 3: Expansion Projects - The company is currently working on an expansion project in the Knowledge City, focusing on automated production lines for consumables and high-end IVD equipment [2] - The expansion project is aimed at enhancing the company's research and development capabilities for biochemical diagnostic reagents [2] Group 4: Profitability Metrics - The gross profit margin in Q1 2023 was better than in 2019, attributed to a more efficient operational structure and economies of scale in production [3]